Type
|
Public |
---|---|
Traded as | NASDAQ: AEMD |
Genre | Biotechnology |
Headquarters | San Diego, California, USA |
Website | www.aethlonmedical.com |
Aethlon Medical Inc. is a public company based in San Diego, California that trades on the NASDAQ under the ticker symbol "AEMD." Aethlon is said to develop medical devices to treat infectious disease and cancer by filtering harmful substances such as viruses from the blood.
In development by Aethlon is the Hemopurifier, described as a single-use disposable cartridge for use with dialysis machines and other blood circulatory pumps. During October, 2014, the Hemopurifier was used as an adjunct therapy in the treatment of a patient who was suffering from Ebola. The patient subsequently recovered, although it was not clear which of several experimental therapies, if any, were responsible for his recovery. The FDA subsequently approved the device for testing in up to 20 infected Ebola cases in the United States.
In AEMD 16 funds of 2195 total. Show all
Fund name | Ticker shares |
---|---|
Vanguard Group, Inc | 0.12M |
MORGAN STANLEY | 66526 |
BlackRock Institutional Trust Company, N.A. | 54499 |
RENAISSANCE TECHNOLOGIES LLC | 27195 |
Alpine Partners VI, LLC | 25000 |
BlackRock Fund Advisors | 17902 |
GEODE CAPITAL MANAGEMENT, LLC | 17321 |
Sigma Planning Corp | 13819 |
Cordasco Financial Network | 13598 |
NORTHERN TRUST CORP | 12248 |
BlackRock Inc. | 10253 |
WELLS FARGO & CO/MN | 2191 |
UBS Group AG | 1649 |
PNC FINANCIAL SERVICES GROUP, INC. | 1454 |
BlackRock Investment Management, LLC | 1193 |